See more : PADAUK Technology Company Limited (6716.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Heidelberg Pharma AG (HPHA.DE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Heidelberg Pharma AG, a leading company in the Biotechnology industry within the Healthcare sector.
- Mendus AB (publ) (IMMU.ST) Income Statement Analysis – Financial Results
- China Zhonghua Geotechnical Engineering Group Co., Ltd. (002542.SZ) Income Statement Analysis – Financial Results
- InPlay Oil Corp. (IPO.TO) Income Statement Analysis – Financial Results
- Palm Jewels Limited (PALMJEWELS.BO) Income Statement Analysis – Financial Results
- Anthera Pharmaceuticals, Inc. (ANTH) Income Statement Analysis – Financial Results
Heidelberg Pharma AG (HPHA.DE)
About Heidelberg Pharma AG
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. It is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for tumors; and HDP-XX for the treatment of solid/hematological tumors. The company is also developing MGTA-ATACs for HSCs, conditioning programs to treat blood cancers/genetic diseases; TAK-ATACs for oncology; and TLX250-CDx, a diagnostic antibody for imaging diagnostics of renal cancer in Phase III trials; urothelial carcinoma or bladder cancer in Phase I study; and triple-negative breast cancer in Phase II study. In addition, the company develops TLX250 (girentuximab), a therapeutic antibody, which is in Phase II study for patients with advanced clear cell renal cell carcinoma; RHB-107, an oral serine protease inhibitor that is in Phase II/III study to treat COVID-19, as well as for the treatment of advanced cholangiocarcinoma; and LH011 for pancreatic cancer. It has licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. for the development and commercialization rights for HDP-101 and HDP-103 in Asia. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.86M | 18.51M | 1.75M | 8.49M | 7.31M | 3.67M | 1.90M | 1.36M | 2.28M | 3.60M | 13.32M | 17.84M | 9.88M | 0.00 | 10.00M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.25M | 4.68M | 4.71M | 5.60M | 3.74M | 2.21M | 956.66K | 809.06K | 1.14M | 1.35M | 3.68M | 6.75M | 4.17M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 6.61M | 13.83M | -2.96M | 2.89M | 3.57M | 1.46M | 943.34K | 552.94K | 1.14M | 2.24M | 9.64M | 11.10M | 5.71M | 0.00 | 10.00M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 67.01% | 74.73% | -169.29% | 34.03% | 48.85% | 39.80% | 49.65% | 40.60% | 50.09% | 62.34% | 72.38% | 62.19% | 57.83% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 28.07M | 26.38M | 18.75M | 18.29M | 10.94M | 10.68M | 9.32M | 6.12M | 4.44M | 5.57M | 12.43M | 12.78M | 15.64M | 19.70M | 21.82M | 20.16M | -16.23M | -10.67M |
| General & Administrative | 5.25M | 4.82M | 3.99M | 3.58M | 3.14M | 2.97M | 2.75M | 1.95M | 4.51M | 3.18M | 4.24M | 4.86M | 5.29M | 4.72M | 4.05M | 4.44M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 1.17M | 496.21K | 392.65K | 281.55K | 191.90K | 206.77K | 222.16K | 341.34K | 482.77K | 3.72M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.25M | 4.82M | 3.99M | 3.58M | 3.14M | 2.97M | 2.75M | 1.95M | 4.51M | 3.18M | 4.24M | 4.86M | 5.29M | 4.72M | 4.05M | 4.44M | 0.00 | 0.00 |
| Other Expenses | -5.51M | 976.59K | 94.21K | -416.35K | -152.45K | 323.00K | 87.00K | 61.00K | 1.23M | 1.11M | 920.00K | 2.37M | -1.84M | -1.31M | -3.01M | -3.21M | 0.00 | 0.00 |
| Operating Expenses | 27.82M | 32.17M | 22.83M | 21.45M | 13.93M | 13.52M | 11.79M | 6.98M | 8.97M | 8.96M | 19.65M | 20.01M | 19.10M | 23.11M | 22.86M | 21.39M | -16.23M | -10.67M |
| Cost & Expenses | 31.07M | 36.85M | 27.54M | 27.05M | 17.67M | 15.72M | 12.74M | 7.79M | 10.11M | 10.31M | 23.33M | 26.75M | 23.26M | 23.11M | 22.86M | 21.39M | -16.23M | -10.67M |
| Interest Income | 1.62M | 235.00K | 494.00K | 13.56K | 0.00 | 0.00 | 0.00 | 1.16K | 3.17K | 86.85K | 83.59K | 30.46K | 6.60K | 25.23K | 157.95K | 972.29K | 0.00 | 0.00 |
| Interest Expense | 761.60K | 840.00K | 494.49K | 13.56K | 0.00 | 0.00 | 218.00K | 19.72K | 545.00 | 118.07K | 160.24K | 508.50K | 547.62K | 5.48K | 7.60K | 11.62K | 0.00 | 0.00 |
| Depreciation & Amortization | 879.00K | 756.58K | 802.86K | 734.00K | 547.00K | 399.00K | 406.24K | 279.89K | 311.59K | 489.15K | 1.72M | 671.86K | 524.15K | 216.51K | 237.33K | 252.71K | 257.77K | 191.23K |
| EBITDA | -18.71M | -16.19M | -24.83M | -17.55M | -9.60M | -11.72M | -10.35M | -6.08M | -6.20M | -5.09M | -3.16M | -8.21M | -12.86M | -22.87M | -12.47M | -20.17M | -21.95M | -17.52M |
| EBITDA Ratio | -189.74% | -87.53% | -1,419.64% | -207.71% | -134.32% | -308.15% | -544.52% | -446.40% | -273.81% | -139.02% | -52.93% | -46.18% | -130.12% | 0.00% | -124.69% | 0.00% | 0.00% | 0.00% |
| Operating Income | -21.21M | -18.33M | -25.63M | -18.56M | -10.36M | -11.67M | -10.75M | -6.36M | -6.52M | -5.58M | -4.96M | -8.91M | -13.38M | -23.11M | -12.86M | -21.39M | -23.93M | -18.25M |
| Operating Income Ratio | -215.13% | -99.03% | -1,464.78% | -218.71% | -141.80% | -318.21% | -565.93% | -467.04% | -285.31% | -155.03% | -37.27% | -49.94% | -135.49% | 0.00% | -128.64% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 863.31K | -604.67K | -507.64K | -84.32K | 0.00 | 0.00 | -217.58K | -18.56K | 2.62K | -31.22K | -76.64K | -478.04K | -540.90K | 19.75K | 150.36K | 960.67K | 0.00 | 0.00 |
| Income Before Tax | -20.35M | -17.79M | -26.14M | -18.37M | -10.14M | -11.67M | -10.97M | -6.38M | -6.51M | -5.61M | -5.04M | -9.39M | -13.92M | -23.09M | -12.71M | -20.43M | 0.00 | 0.00 |
| Income Before Tax Ratio | -206.38% | -96.07% | -1,493.79% | -216.41% | -138.78% | -318.21% | -577.38% | -468.40% | -285.20% | -155.90% | -37.85% | -52.62% | -140.97% | 0.00% | -127.14% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.92M | 494.49K | 4.56K | 5.01K | 570.46K | 417.42K | 9.45K | 37.74K | 93.19K | 121.00 | 2.57K | 1.61K | 6.37K | 15.46K | 14.79K | 0.00 | 0.00 |
| Net Income | -20.35M | -19.70M | -26.63M | -18.37M | -10.15M | -11.67M | -10.97M | -6.39M | -6.55M | -5.70M | -5.04M | -9.39M | -13.93M | -23.09M | -12.73M | -20.45M | 0.00 | 0.00 |
| Net Income Ratio | -206.38% | -106.42% | -1,522.05% | -216.47% | -138.84% | -318.21% | -577.38% | -469.09% | -286.85% | -158.49% | -37.85% | -52.64% | -140.99% | 0.00% | -127.29% | 0.00% | 0.00% | 0.00% |
| EPS | -0.44 | -0.53 | -0.82 | -0.61 | -0.36 | -0.41 | -0.76 | -0.53 | -0.75 | -0.66 | -0.61 | -1.37 | -2.54 | -5.13 | -3.55 | -6.36 | 0.00 | 0.00 |
| EPS Diluted | -0.44 | -0.53 | -0.82 | -0.61 | -0.36 | -0.41 | -0.76 | -0.51 | -0.72 | -0.66 | -0.61 | -1.37 | -2.54 | -5.13 | -3.55 | -6.36 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 46.60M | 37.24M | 32.50M | 29.90M | 28.21M | 28.21M | 14.37M | 11.98M | 8.78M | 8.67M | 8.28M | 6.86M | 5.48M | 4.50M | 3.59M | 3.22M | 3.22M | 3.22M |
| Weighted Avg Shares Out (Dil) | 46.60M | 37.24M | 32.50M | 29.90M | 28.21M | 28.21M | 14.37M | 12.47M | 9.15M | 8.67M | 8.28M | 6.86M | 5.48M | 4.50M | 3.59M | 3.22M | 3.22M | 3.22M |
Source: https://incomestatements.info
Category: Stock Reports